Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 5—May 2024
Synopsis

Case Series of Jamestown Canyon Virus Infections with Neurologic Outcomes, Canada, 2011–2016

Vanessa Meier-StephensonComments to Author , Michael A. Drebot, Kristina Dimitrova, Melanie DiQuinzio, Kevin Fonseca, David Forrest, Todd Hatchette, Muhammad Morshed, Glen Patriquin, Guillaume Poliquin, Lynora Saxinger, Bouchra Serhir, Raymond Tellier, Christian Therrien, Linda Vrbova, and Heidi Wood
Author affiliations: University of Alberta, Edmonton, Alberta, Canada (V. Meier-Stephenson, L. Saxinger); Public Health Agency of Canada, Winnipeg, Manitoba, Canada (M.A. Drebot, K. Dimitrova, G. Poliquin, L. Vrbova, H. Wood); Dalhousie University, Halifax, Nova Scotia, Canada (M. DiQuinzio, T. Hatchette, G. Patriquin); Alberta Precision Labs, Calgary, Alberta, Canada (K. Fonseca); University of British Columbia, Nanaimo, British Columbia, Canada (D. Forrest); British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada (M. Morshed); Institut National de Santé Publique du Québec, Québec City, Quebec, Canada (B. Serhir, C. Therrien); McGill University Health Centre, Montreal, Quebec, Canada (R. Tellier)

Main Article

Table

CSF and serologic characteristics of patient samples in case series of Jamestown Canyon virus infections with neurologic outcomes, Canada, 2011–2016*

Case no. Province Date Age, y/sex CSF parameters† JCV IgM, blood PRNT titer, acute serum PRNT titer, convalescent serum IgM or PRNT titer, CSF
1
 BC
 Jun 2013
 66/M
 50 × 109 leukocytes/L, 85% lymphocytes; 1.45 g/L protein; 3.0 mmol/L glucose
+, Jun 23; +, Jun 30
 JCV, 1:40, Jun 23; JCV, 1:80, Jun 30; no SSHV reported
 NA
 JCV, + IgM, 1:10 PRNT, Jun 26; SSHV, – IgM/PRNT
2
 AB
 Sep 2011
 48/M
 246 × 109 leukocytes/L, 1% neutrophils, 98% lymphocytes; 1.73 g/L protein; 4.0 mmol/L glucose
+, Sep 27
 JCV, 0, Sep 27; SSHV, 0; Sep 27
 JCV, >1:80, Oct 4; SSHV, 0; Oct 4
 JCV, + IgM, Sep 26
3
 AB
 Sep 2013
 68/M
 321 × 109 leukocytes/L, 52% neutrophils, 36% lymphocytes; 0.54 g/L protein; 4.7 mmol/L glucose
+, Sep 26
 JCV, 0, Sep 26; SSHV, 0; Sep 26
 JCV, 1:40, Nov 5; SSHV, 0; Nov 5
 NA
4
 QC
 Aug 2011
 53/M
 5 × 109 leukocytes/L, 0.10 g/L protein, 5.3 mmol/L glucose
+, Aug 26; +, Sep 19; +, Sep 30
 JCV, 1:640, Aug 26; SSHV, 1:160; Aug 26
 JCV, 1:2,560, Sep 19; SSHV, 1:640; Sep 19; JCV, 1:640, Sep 30; SSHV, 1:160, Sept 30
 JCV, + IgM, – PRNT, Aug 26; JCV,+ IgM, 1:16 PRNT, Sep 6
5 NS Jun 2016 70/M 41 × 109 leukocytes/L, 100% lymphocytes; 0.67 g/L protein; 3.2 mmol/L glucose +, JCV; +, SSHV JCV, 1:320, Jul 29; SSHV, 1:40; Jul 29 JCV, 1:1,280, Aug 11; SSHV, 1:80, Aug 11 JCV, + IgM, 1:4 PRNT, Jul 27; SSHV, – IgM/PRNT

*AB, Alberta; BC, British Columbia; CSF, cerebrospinal fluid; JCV, Jamestown Canyon virus; NA, not applicable; NS, Nova Scotia; PRNT, plaque reduction neutralization test; QC, Quebec; SSHV, Snowshoe Hare virus; +, positive; –, negative. †Reference ranges for CSF: leukocyte count, 0–5 × 109 cells/L; protein, 0.2–0.45 g/L; glucose, 2.2–3.9 mmol/L.

Main Article

Page created: March 12, 2024
Page updated: April 23, 2024
Page reviewed: April 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external